3.01

1.69% 0.05

After Hours: 3.03 0.02 +0.66%

Recursion Pharmaceuticals Inc (RXRX)

Overview News Price History Option Chain Financials Why RXRX Down? Discussions Forecast

Recursion Pharmaceuticals Inc stock is traded at $3.01, with a volume of 21.66M. It is up +1.69% in the last 24 hours and down -14.49% over the past month. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

Previous Close:

$2.96

Open:

$3.03

24h Volume:

21.66M

Relative Volume:

1.10

Market Cap:

$1.60B

Revenue:

$66.41M

Net Income/Loss:

$-559.78M

P/E Ratio:

-2.5037

EPS:

-1.2022

Net Cash Flow:

$-328.09M

1W Performance:

+4.15%

1M Performance:

-14.49%

6M Performance:

-34.57%

1Y Performance:

-53.62%

1-Day Range:

$2.99

$3.13

1-Week Range:

$2.90

$3.13

52-Week Range:

$2.77

$7.18

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Name

Recursion Pharmaceuticals Inc

Sector

Healthcare (1074)

Industry

Biotechnology (599)

Phone

(385) 269-0203

Address

41S RIO GRANDE STREET, SALT LAKE CITY

Employee

600

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

RXRX's Discussions on Twitter

Compare RXRX vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RXRX Recursion Pharmaceuticals Inc	3.01	1.57B	66.41M	-559.78M	-328.09M	-1.2022
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-17-25	Upgrade	JP Morgan	Neutral → Overweight
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight
May-22-23	Initiated	Morgan Stanley	Equal-Weight
Mar-16-23	Initiated	Needham	Buy
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-21	Initiated	Berenberg	Buy
May-11-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Goldman	Neutral
May-11-21	Initiated	JP Morgan	Neutral
May-11-21	Initiated	KeyBanc Capital Markets	Overweight
May-11-21	Initiated	SVB Leerink	Outperform

View All

Recursion Pharmaceuticals Inc Stock (RXRX) Latest News

Jul 27, 2026

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Jul 27, 2026

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance Singapore

Jul 27, 2026

Recursion Pharmaceuticals, Inc. Class A Revenue Breakdown – BIVA:RXRX - TradingView

Jul 27, 2026

RXRX (RXRX) insider details 50,000-share planned sale and recent stock trades - Stock Titan

Jul 27, 2026

RXRX|Recursion Pharmaceuticals Inc|Price:3.030| - TradingKey

Jul 27, 2026